Cell- and gene-therapy-focused ElevateBio has let go of 17% of staffers as part of the company’s second layoff round since ...

As it gears up to submit an approval application next year, Wave Life Sciences has presented fresh phase 2 data showing its ...

The Senate has confirmed President Donald Trump’s pick Jayanta Bhattacharya, M.D., Ph.D., to lead the National Institutes of ...

The Italian neuromodulation startup Newronika has secured a European approval for its closed-loop, adaptive implant for ...

Supira Medical has raised $120 million to complete the clinical development of its temporary heart pump, designed for ...

Responding to the progress of its obesity pipeline, the Chinese biotech is stepping up its investment in metabolic disease ...

ImmuneOnco Biopharmaceuticals has shown Chinese biotechs are far from immune to the pressures to prioritize pipelines. | ...

Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli Lilly castoff solely on endometrial cancer.

The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. | The drug discovery pact between Charles River Laboratories, Valo Health and ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.

Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...